Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aducanumab re-dosing safety study in Alzheimer's disease (EMBARK)
NCT04241068Phase 3Terminated
- Sponsor
- Biogen
- Start
- Mar 2020
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
Phase 3, open-label, single-arm trial of aducanumab in Alzheimer's disease (AD), sponsored by Biogen. Primary endpoints: Treatment-Emergent Adverse Events, Adverse Events Leading to Treatment Discontinuation and Study Withdrawal and 3 more. Started Mar 2020; status: terminated.
02
Drugs
aducanumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04241068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04241068.